Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane in Bladder Cancer Chemoprevention
NCT03517995Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2020
- Primary completion
- Dec 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sulforaphane in bladder cancer, sponsored by Moffitt Cancer Center. Planned start Apr 2020; status: withdrawn.
02
Drugs
sulforaphane
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03517995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517995.